Skip to main content
Premium Trial:

Request an Annual Quote

Heiner Dreismann, Thomas Hudson, David Cooper, Didier Hirsch, Hilliard Terry

Premium
Heiner Dreismann has been named to the board of directors at Nanogen, the company said this week.
 
Dreismann is the current CEO of FasTraQ and previously served as president and CEO of Roche Molecular Systems
 
Dreismann became a director of Iconix Biosciences last week and last month became a director of GeneNews, formerly ChondroGene.
 

 
The Ontario Institute for Cancer Research recently named Thomas Hudson as its new president and scientific director.
 
An early member of the Human Genome Project, Hudson was a director at the Whitehead Institute for Biomedical Research at the Massachusetts Institute of Technology, and at the MIT Center for Genome Research. He later became the founder and director of the McGill University and Genome Quebec Innovation Centre, where he will remain until 2007.
 

 
Agilent Technologies this week said that Senior Vice President of Finance and Treasurer David Cooper will leave the company effective Nov. 3 to join Art.com as its CFO.
 
Corporate controller Didier Hirsch will become vice president and controller and Hilliard Terry, director of investor relations, will move into the role of vice president and treasurer at Agilent. Terry will continue to serve in his present position until the company names a successor.

The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.